K Pharma

K Pharma EBITDA per Employee

The EBITDA per Employee of K Pharma (4896.T) as of Oct 21, 2026 is -70.47 M JPY. In the previous year, EBITDA per Employee was -64.33 M JPY — a change of 9.53% (lower).

EBITDA per Employee

-70.47 MJPY

YoY

9.53%

Last updated:

EBITDA per Employee of K Pharma is 2025 -70.47 M JPY. EBITDA per Employee of K Pharma was 2024 -64.33 M JPY. It decreases by 9.53% lower compared to the previous year.

The K Pharma EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2021
-16.85 M JPY
Jan 1, 2022
-27.21 M JPY
Jan 1, 2023
28.16 M JPY
Jan 1, 2024
-64.33 M JPY
Jan 1, 2025
-70.47 M JPY
The K Pharma EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-70.47 MJPY+9.53%
-64.33 MJPY-328.47%
28.16 MJPY-203.47%
-27.21 MJPY+61.52%
-16.85 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

K Pharma Stock analysis

What does K Pharma do? K Pharma Inc generates revenue through the research, development, manufacture, and sale of pharmaceuticals within a single segment. The company focuses on induced pluripotent stem cell (iPS) drug discovery, creating neural progenitor cells from iPS cells for spinal cord injury treatments. These cells are cryopreserved and transplanted in 200,000-cell injections. Additionally, K Pharma Inc develops regenerative medicine products, targeting medical applications for nerve-related conditions. The firm's primary customers are healthcare providers and medical institutions requiring advanced treatments for spinal cord injuries and regenerative therapies. The company's core products include iPS-derived neural progenitor cell therapies and regenerative medicine solutions. These are sold to hospitals and clinics specializing in neurology and regenerative medicine. K Pharma Inc's business model centers on leveraging iPS cell technology to create innovative treatments, with revenue derived from the sale of these specialized pharmaceutical and regenerative medicine products. The firm's single-segment operations ensure focused development and commercialization of its iPS-based therapies. K Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about K Pharma stock

EBITDA per Employee of K Pharma is -70.47 M JPY in 2025.

EBITDA per Employee of K Pharma changed from -64.33 M JPY to -70.47 M JPY, representing a 9.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee K Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's K Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — K Pharma

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — K Pharma